GT200600364A - ORGANIC COMPOUNDS - Google Patents

ORGANIC COMPOUNDS

Info

Publication number
GT200600364A
GT200600364A GT200600364A GT200600364A GT200600364A GT 200600364 A GT200600364 A GT 200600364A GT 200600364 A GT200600364 A GT 200600364A GT 200600364 A GT200600364 A GT 200600364A GT 200600364 A GT200600364 A GT 200600364A
Authority
GT
Guatemala
Prior art keywords
organic compounds
terbutoxi
campotecine
topoisomerase
microparticles
Prior art date
Application number
GT200600364A
Other languages
Spanish (es)
Inventor
Isabel Ottinger
Oskar Kalb
Walter Stebler
Agnes Taillardat
Wolfgang Wirth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600364(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600364A publication Critical patent/GT200600364A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS EN MICROPARTÍCULAS, EN DONDE EL AGENTE ACTIVO ES UN INHIBIDOR DE TOPOISOMERASA I, EN PARTICULAR 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA COMPUESTO A, QUE ES ÚTIL PARA EL TRATAMIENTO Y LA PREVENCIÓN DE ENFERMEDADES PROLIFERATIVAS, INCLUYENDO CÁNCER. T2006THE PRESENT INVENTION REFERS TO PHARMACEUTICAL COMPOSITIONS IN MICROPARTICLES, WHERE THE ACTIVE AGENT IS AN INHIBITOR OF TOPOISOMERASE I, IN PARTICULAR 7-TERBUTOXI-IMINO-CAMPOTECINE COMPOSED TO, WHICH IS USEFUL FOR THE PROCESSING OF PREVENTION. INCLUDING CANCER. T2006

GT200600364A 2005-08-10 2006-08-08 ORGANIC COMPOUNDS GT200600364A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10

Publications (1)

Publication Number Publication Date
GT200600364A true GT200600364A (en) 2007-03-19

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600364A GT200600364A (en) 2005-08-10 2006-08-08 ORGANIC COMPOUNDS

Country Status (20)

Country Link
EP (1) EP1915132A1 (en)
JP (1) JP2009504616A (en)
KR (1) KR20080034989A (en)
CN (1) CN101287448A (en)
AR (1) AR055602A1 (en)
AU (1) AU2006277879A1 (en)
BR (1) BRPI0614757A2 (en)
CA (1) CA2618084A1 (en)
EC (1) ECSP088166A (en)
GT (1) GT200600364A (en)
IL (1) IL189076A0 (en)
MA (1) MA29735B1 (en)
MX (1) MX2008001965A (en)
NO (1) NO20081213L (en)
PE (1) PE20070232A1 (en)
RU (1) RU2008108885A (en)
TN (1) TNSN08062A1 (en)
TW (1) TW200800195A (en)
WO (1) WO2007017514A1 (en)
ZA (1) ZA200800726B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (en) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti ESTERS OF L-CARNITINE OR ALCANOYL L-CARNITINE USABLE CATIONIC COMELIPIDS FOR INTRACELLULAR PLACING OF COMPOUNDS
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (en) * 2004-11-19 2006-06-19 ORGANIC COMPOUNDS

Also Published As

Publication number Publication date
TW200800195A (en) 2008-01-01
CN101287448A (en) 2008-10-15
ECSP088166A (en) 2008-03-26
AR055602A1 (en) 2007-08-29
MX2008001965A (en) 2008-03-26
RU2008108885A (en) 2009-09-20
AU2006277879A1 (en) 2007-02-15
TNSN08062A1 (en) 2009-07-14
ZA200800726B (en) 2009-08-26
PE20070232A1 (en) 2007-04-09
KR20080034989A (en) 2008-04-22
MA29735B1 (en) 2008-09-01
CA2618084A1 (en) 2007-02-15
WO2007017514A1 (en) 2007-02-15
IL189076A0 (en) 2008-08-07
EP1915132A1 (en) 2008-04-30
BRPI0614757A2 (en) 2011-04-12
JP2009504616A (en) 2009-02-05
NO20081213L (en) 2008-05-13

Similar Documents

Publication Publication Date Title
GT200900027A (en) ORGANIC COMPOUNDS
ECSP088676A (en) PIRAZOLQUINOLONAS AS POWERFUL PARP INHIBITORS
CL2011000134A1 (en) Compounds derived from aminophenoxyindazoles, c-met inhibitors; pharmaceutical composition comprising these compounds; and its use to treat cancer.
CL2010001361A1 (en) Compounds derived from piperidine-carboxamide, renin inhibitors; pharmaceutical composition that includes them; and use in the treatment or prevention of a circulatory disease, hypertension and / or various organic damages attributable to hypertension.
SV2009002899A (en) DIARILURES FOR THE TREATMENT OF PULMONARY HYPERTENSION
CR20140544A (en) COMPOUNDS TO INHIBIT THE MYTHICAL PROGRESSION
CO6331446A2 (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE COMBINATION OF AN ANTIMITOTIC AGENT AND AN INHIBITING COMPOUND OF AURORA QUINASA, USEFUL IN ANTI-TARGET TREATMENT
UY30220A1 (en) TETRAHYDROPIRIDOTIENOPIRIMIDINA COMPOUNDS AND METHODS FOR USE
CL2007002234A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF PROLIFERATIVE DISEASES.
CL2011000691A1 (en) Compounds derived from substituted nicotinamide; pharmaceutical composition that includes them; use for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CL2007003226A1 (en) COMPOUNDS DERIVED FROM PIRIDINONA; PHARMACEUTICAL COMPOSITION; AND USE TO TREAT CANCER.
CO6531502A2 (en) AMINOTRIAZOLOPIRIDINAS AND ITS USE AS CINASE INHIBITORS
CR10748A (en) INDOL COMPOUND
BRPI0803374A2 (en) polyhydroxy compounds as polymerization extinguishing agents
PA8850801A1 (en) USEFUL COMPOUNDS TO INHIBIT CHK1
CL2008002369A1 (en) Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
PA8667201A1 (en) NEW PHARMACEUTICAL COMPOUNDS
GT200500310A (en) ORGANIC COMPOUNDS
CL2007002519A1 (en) COMPOUNDS DERIVED FROM AMINOPIRIDINE, SELECTIVE INHIBITORS ON AURORA A; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL COMBINATION THAT INCLUDES SUCH COMPOUNDS, USEFUL TO INHIBIT THE GROWTH OF TUMOR CELLS
DOP2010000302A (en) ANTAGONISTS OF THE HEDGEHOG TRAJECTORY OF DISTTITUTED FTALAZINA
PA8846901A1 (en) AKT AND P70 S6 CINASE INHIBITORS.
UY30778A1 (en) COMPOUNDS OF 5,6-DIHIDRO-1H-PIRIDIN-2-ONA
GT200500311A (en) ORGANIC COMPOUNDS
CL2011000165A1 (en) Compounds derived from indolinones; pharmaceutical composition comprising said compound; and use of the compound for the treatment and / or prevention of cancer, infections, inflammatory and autoimmune diseases.
CR10199A (en) BENZIMIDAZOL DERIVATIVES